ANZLG HD3/TROG 99.01 - Hodgkins Disease IFRT - HD3

By w.paterson
14 August, 2021
0 Comments

An ANZLG / TROG Prospective Study of Limited Chemotherapy and Involved Field Radiotherapy for Patients With Clinical Stage I-II Hodgkin’s Disease

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

18 October, 2022

NINJA Radiation Therapy Trial participant tells his journey to treatment

The journey to becoming the 200th participant for the

6 September, 2022

The gift that kept on giving

The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing

Join us to raise $35,000

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

An ANZLG / TROG Prospective Study of Limited Chemotherapy and Involved Field Radiotherapy for Patients With Clinical Stage I-II Hodgkin’s Disease

TROG 99.02 – Anal Canal

TROG 98.06 – Oesophagus

Related Post

NINJA Radiation Therapy Trial participant tells his journey to treatment

The gift that kept on giving

Join us to raise $35,000

ANZLG HD3/TROG 99.01 – Hodgkins Disease IFRT – HD3

An ANZLG / TROG Prospective Study of Limited Chemotherapy and Involved Field Radiotherapy for Patients With Clinical Stage I-II Hodgkin’s Disease

TROG 99.02 – Anal Canal

TROG 98.06 – Oesophagus

Related Post

NINJA Radiation Therapy Trial participant tells his journey to treatment

The gift that kept on giving

Join us to raise $35,000